Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, has announced that it is advancing to the second cohort in its pharmacokinetics study of AD04. This progression foll...
The Real Wojak : Depends on where you bought it, stock has ran a couple times, had good opportunities from the lows if you bought the dips.
HotShot369 : Most stocks aren't crap. just how you use the stock is.
Arrayfunction : What were you hoping to do with it exactly? When dealing with anything in drug development, you are talking years at least before they have a marketable product. This one seems fairly healthy for the industry. With 9x assets to liabilities, they aren't going to fold unless their drugs flop. Which is why biotech is always speculation
73367072 OP : You guys are right , I’m just getting emotional , my average is below $2. I’ll wait